RIGScan is an investigational, tumor-specific, radio-labeled monoclonal antibody targeting agent. It may be used during surgery to Identify cancerous tissue undetectable by traditional diagnostic and intraoperative techniques. The RIGScan agent may enable more effective colorectal cancer surgeries leading to improved patient survival.
Before surgery, a cancer patient is injected with one of the RIGScan targeting agents which circulates throughout the patient’s body and binds specifically to cancer cell antigens or receptors. Concentrations of the RIGS within affected tissue are then detected using a gamma probe and direct the surgeon to targeted tissue for removal.
RIGScan has completed clinical studies for the enhanced detection of occult cancer in Stage IV primary or recurrent colorectal cancer.